Vimarsana
Biggest News Aggregation in the World

Page 31 - Groupb Streptococcus News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Groupb Streptococcus. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Groupb Streptococcus Today - Breaking & Trending Today

Babies surviving GBS disease 'more likely to need special educational support' - Vimarsana News

Babies surviving GBS disease 'more likely to need special educational support'

Babies surviving GBS disease ‘more likely to need special educational support’ (Danny Lawson/PA) Babies who survive a potentially deadly disease caused by a common type of bacteria passed on from their mothers may be twice as likely to have life-changing disabilities and require special educational support than those not infected, research suggests. Scientists in the UK and Europe found infants who develop invasive Group B Streptococcus (GBS) disease during the first days and months of their lives are at risk of having lasting neurodevelopmental impairments (NDI) – disabilities in the f...

Babies who survive Group B streptococcal disease more likely to require special educational support into their second decade - Vimarsana News

Babies who survive Group B streptococcal disease more likely to require special educational support into their second decade

Date Time Share Babies who survive Group B streptococcal disease more likely to require special educational support into their second decade London School of Hygiene & Tropical Medicine Largest study of its kind shows infected babies face greater risk of neurodevelopmental impairments and underlines need for follow-up care for survivors and maternal GBS vaccines Invasive Group B Streptococcus (GBS) disease, notably meningitis, during the first days and months of a baby’s life can have persistent effects for children and hence their families, according to new research. Published in the Lanc...

Global Infectious Diseases Partnering Deals 2014-2021: Headline Value, Upfront Payment, Milestone Payments and Royalty Rates - Vimarsana News

Global Infectious Diseases Partnering Deals 2014-2021: Headline Value, Upfront Payment, Milestone Payments and Royalty Rates

Share this article Share this article ResearchAndMarkets.com's offering. Global Infectious Diseases Partnering 2014 to 2021 provides the full collection of Infectious Diseases disease deals signed between the world's pharmaceutical and biotechnology companies since 2014. Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element. The report takes readers through the ...

MinervaX raises upsized EUR 47.4M (USD 57M) Series B to advance its novel Group B Streptococcus vaccine through mid-stage clinical trials - Vimarsana News

MinervaX raises upsized EUR 47.4M (USD 57M) Series B to advance its novel Group B Streptococcus vaccine through mid-stage clinical trials

Share: COPENHAGEN, Denmark, Dec. 15, 2020 /PRNewswire/ -- MinervaX, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), announced today that it has raised an upsized EUR 47.4 million Series B financing. The round included new investors Sanofi Ventures, Wellington Partners, Adjuvant Capital, and Industrifonden, along with existing investors Novo Holdings REPAIR Impact Fund, Sunstone Life Science Ventures, and LF Investment. Proceeds will advance the clinical development of MinervaX's novel GBS vaccine through Phase II clinical trials,...

Novo Holdings REPAIR Impact Fund supports upsized MinervaX EUR 47.4M Series B financing to advance novel vaccine against Group B Streptococcus - Vimarsana News

Novo Holdings REPAIR Impact Fund supports upsized MinervaX EUR 47.4M Series B financing to advance novel vaccine against Group B Streptococcus

(1) - On the back of highly promising Phase Ib data, MinervaX has raised financing from leading investors to accelerate development of its novel vaccine through the end of Phase II trials and preparations for Phase III pivotal trials - Novel vaccine candidate offers viable alternative to antibiotics, thereby strategically aligned with REPAIR Impact Fund's mission to combat antimicrobial resistance (AMR) - - Group B Streptococcus (GBS) is one of the leading causes of stillbirth and infant mortality representing a significant unmet need globally, including in the US and Europe; nearly one i...